Handelsavisen
prelaunch
Companies ›Healthcare ›INVA.NS
IN
INVA.NS — NSE (India) Healthcare Facilities & Services

Invicta Diagnostic Ltd

$89,50
Open in Charts → Attach watcher ⌖
— —
USD
Set alert
Last 30 days
1D5D1M3M6MYTD1Y5YMax
Live price chart loads from the market-data widget.
Mcap
—
P/E
—
EV / Rev
—
Div yield
—
Op margin
—
ROE
—
Net margin
—
Debt / equity
—
Beta
—
52w range
—
Volume
—
Day range
—
Prev close
—
Open
—
Next earnings
2026-10-28
Ex-dividend
—
TR 1Y
—
About

Invicta Diagnostic Ltd provides diagnostic services and related healthcare solutions.

Business. Invicta Diagnostic Ltd (INVA.NS) is a healthcare services and equipment company primarily engaged in pharmaceutical activities. The firm operates within the Healthcare Facilities & Services industry, generating revenue through service-based models. Headquartered in India, the company is listed on the National Stock Exchange of India. Specific details regarding operating segments and geographic revenue mix are not disclosed.

Classification92 %
SectorHealthcare
Business sectorHealthcare Services & Equipment
IndustryHealthcare Facilities & Services
ActivityPharmaceuticals
Generated · model-assisted
Sell-side consensus
BUY5 analysts
4 buy0 hold1 sell
Avg 12m price target35,50

Analyst recommendations

5 analysts · consensus Buy
Buy4
Hold0
Sell1
12-month price target
35,50
Consensus of sell-side coverage.
Upcoming events
  • EarningsQ3 2026 earnings (expected)2026-10-28 · estimated
See all catalysts →

At a glance

Score
—
not yet scored
Valuation
—
valuation pending
Analysts→
Buy
5 analysts · indicative
Ownership→
Arrowstreet Capital, Limited Partnership
largest disclosed fund holder
Profitability
—
not yet wired
Quality
—
not yet scored

What drives this business

The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.

— missing data

News & coverage

0
  • No recent newsroom coverage mentioning INVA.

    • Sector rotation

    Sector1D1Mvs mkt
    Materials+2,3 %+6,6 %+1,7 %
    Communication Services+2,2 %−5,5 %+1,6 %
    Energy+0,6 %+3,3 %+0,0 %
    Health Care · THIS SECTOR+0,6 %−0,8 %+0,0 %
    Information Technology+0,6 %+6,7 %+0,0 %
    Consumer Discretionary+0,4 %+7,6 %−0,2 %
    Financials−0,3 %−2,8 %−0,9 %
    Consumer Staples−0,4 %+2,5 %−1,0 %
    Real Estate−0,7 %+10,9 %−1,3 %
    Industrials−1,9 %−3,1 %−2,5 %
    Utilities−1,9 %+28,2 %−2,5 %

    Developing storylines

    No tracked sagas currently linked to INVA.NS. Browse all sagas →

    Analysis

    AI analysis
    Generated · analysis pipeline · tier hybrid · as of 2026-08-04 ↑ At a glance

    Opportunity

    — missing data

    Upcoming catalysts

    Scheduled public events. Informational only — not investment advice.

    • Company
    • EarningsQ3 2026 earnings (expected)2026-10-28 · estimated
    • Macro
    • Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
    • Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
    • Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
    • Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
    • Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
    • Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
    • Macro & political
    • ElectionSE Swedish Election2026-09-14 · SE
    • ElectionUS U.S. Midterms2026-11-03 · US
    • ElectionFR French Legislative2027-06-01 · FR
    • Congressional trades
    • CongressGeorge Whitesides — Innoviva, Inc. - Common Stock2025-03-25 · Democrat · CA · Sale · $250,001 - $500,000

    Pre-earnings brief

    — missing data

    Signals & dispatch

    peak dispatch · —

    Composite-score breakdown

    Synthesis

    Business

    Invicta Diagnostic Ltd (INVA.NS) is a healthcare services and equipment company primarily engaged in pharmaceutical activities. The firm operates within the Healthcare Facilities & Services industry, generating revenue through service-based models. Headquartered in India, the company is listed on the National Stock Exchange of India. Specific details regarding operating segments and geographic revenue mix are not disclosed.

    Classification92 %
    SectorHealthcare
    Business sectorHealthcare Services & Equipment
    IndustryHealthcare Facilities & Services
    ActivityPharmaceuticals
    AI synthesis
    GENERATED

    The company's capital structure shows no dilution risk, with basic and diluted shares outstanding being equal at 12,571,973 shares. However, liquidity risk could not be assessed due to missing balance-sheet inputs and absence of going-concern language in source documents. No valuation snapshot data is available to evaluate profitability or returns relative to industry benchmarks.

    The company's revenue concentration and geographic exposure are not disclosed in available documents, preventing assessment of segment or regional risk. No financial history or outlook data is available to determine growth trajectory or revenue trends.

    Risk assessment indicates low dilution potential, but liquidity risk remains unassessed due to missing financial data. No recent filings or transcripts are available to identify material events or strategic developments.

    Key takeaways
    • The company shows no current dilution risk with equal basic and diluted share counts
    • Liquidity risk assessment is incomplete due to missing balance-sheet data
    • No valuation metrics are available for comparison to industry benchmarks
    • Revenue concentration and geographic exposure remain undisclosed
    • No recent financial or strategic developments are documented in available sources
    • "margin_outlook_rationale": "Unable to assess margin outlook due to lack of financial data",

    Bull / Bear case

    Generated · model-assisted
    — missing data

    In focus — financials by report

    Valuation FY

    Market price
    $89,50
    Market cap
    —
    Enterprise valueⓘ
    —
    P/Eⓘ
    —
    Non-GAAP P/Eⓘ
    —
    EV / Revenueⓘ
    —
    EV / Op incomeⓘ
    —
    EV / OCFⓘ
    —
    P / Bⓘ
    —
    P / Tangible bookⓘ
    —
    Tangible book
    —
    Net cashⓘ
    —
    Current ratioⓘ
    —
    Debt / equityⓘ
    —
    ROAⓘ
    —
    ROEⓘ
    —
    Cash conversionⓘ
    —
    CapEx / revenueⓘ
    —
    SBC / revenueⓘ
    —
    Dilution ratioⓘ
    0.0%

    Revenue by segment

    Market share

    — missing data

    Business relationships

    Business relationships18 disclosed relationships · 1 type · extracted from filings & disclosures
    Subsidiaries18
    EX21:01b8016fdce4EX21:01b8016fdce4Subsidiarie97%Source ↗
    EX21:13f5efde3066EX21:13f5efde3066Subsidiarie97%
    EX21:17e81f0f3358EX21:17e81f0f3358Subsidiarie97%
    EX21:32f987ecd367EX21:32f987ecd367Subsidiarie97%Source ↗
    EX21:3a2ea2784784EX21:3a2ea2784784Subsidiarie97%
    EX21:405a5f7b283bEX21:405a5f7b283bSubsidiarie97%
    EX21:4508241d6d52EX21:4508241d6d52Subsidiarie97%
    EX21:4a390e81fbf8EX21:4a390e81fbf8Subsidiarie97%
    EX21:613dec104f19EX21:613dec104f19Subsidiarie97%
    EX21:669c79b3b078EX21:669c79b3b078Subsidiarie97%
    EX21:77f1a3cccbefEX21:77f1a3cccbefSubsidiarie97%
    EX21:92d94c5ff2f8EX21:92d94c5ff2f8Subsidiarie97%
    EX21:a6c5a8316ef5EX21:a6c5a8316ef5Subsidiarie97%
    EX21:ad5736686512EX21:ad5736686512Subsidiarie97%Source ↗
    EX21:bae37c1813a9EX21:bae37c1813a9Subsidiarie97%
    EX21:cd335b77960dEX21:cd335b77960dSubsidiarie97%
    EX21:e137d6178e90EX21:e137d6178e90Subsidiarie97%
    EX21:e9fb9ad9ddf2EX21:e9fb9ad9ddf2Subsidiarie97%Source ↗

    Supply chain

    — missing data

    Peer comparison

    — missing data

    Market position

    Stress test

    — missing data

    Predictor forecast

    Next quarternear-term
    Earnings · next quarterconf 45 %
    EPS
    Consensus EPS
    3,98
    Predicted surprise
    -0,08
    Beat probability
    45 %
    Analysts
    5
    Other metrics
    Revenue
    —
    no estimate
    Segment revenue
    —
    no estimate
    Margin
    —
    no estimate
    Segment margin
    —
    no estimate
    as of 2026-06-25 · Earnings Surprise V1
    Period note: consensus is not fiscal-period-aligned at source — read as consensus vs the last reported actual, not a calibrated same-quarter surprise.
    Corporate eventM&A horizon
    M&A probabilityconf 3 %
    Probability
    3 %
    Base rate
    3 %
    Band
    —
    180-day horizon · target 2027-01-28 · 1,0× base rate
    No acquirer candidates identified by the signal model.
    Probabilistic model output — not investment advice. · generated 2026-08-04

    Options

    — missing data

    Short squeeze

    — missing data

    Earnings-call key lines

    — missing data

    Estimate revisions

    consensus EPS · 26-week trend
    — missing data

    Sell-side observations

    Low$18,00
    Mean$35,50
    Median$39,00
    High$46,00
    Spot$89,50
    −60.3 %implied to mean12-month sell-side price targets · ▲ spot

    Themes

    — missing data

    ESG

    — missing data

    Risk factors

    Dilution riskLow
    Liquidity riskUnknown

    Benchmarks vs cohort

    No cohort benchmark data available for this issuer yet.

    Corporate actions / M&A

    M&A probabilityconf —
    Probability
    3 %
    Base rate
    3 %
    Band
    Low
    180-day horizon · target 2027-01-28 · 1,0× base rate
    No acquirer candidates identified by the signal model.
    Corporate actionsNo corporate-action source connected yet — splits, dividends and buyback events are not tracked for this company. Honest-dim (no data fabricated).

    FX exposure

    — missing data

    Comparable transactions

    — missing data

    Derivatives & instruments

    Derivative transactions

    Net acquired 486 916 sh8 grants8 insiders
    • Linden JosephineDirector · Non-statutory Stock Option → Common StockAcquired 9 166 @ $21,80grant · 2026-05-18
    • DiPaolo MarkDirector · Non-statutory Stock Option → Common StockAcquired 10 000 @ $22,99grant · 2026-05-04
    • Haimovitz JulesDirector · Non-statutory Stock Option → Common StockAcquired 10 000 @ $22,99grant · 2026-05-04
    • Basso StephenChief Financial Officer · Non-statutory Stock Option → Common StockAcquired 93 750 @ $22,99grant · 2026-05-04
    • Schlesinger Sarah J.Director · Non-statutory Stock Option → Common StockAcquired 10 000 @ $22,99grant · 2026-05-04
    • Zhen MarianneChief Accounting Officer · Non-statutory Stock Option → Common StockAcquired 31 500 @ $22,99grant · 2026-05-04
    • Raifeld PavelDirector, Chief Executive Officer · Non-statutory Stock Option → Common StockAcquired 312 500 @ $22,99grant · 2026-05-04
    • Small Derek ADirector · Non-statutory Stock Option → Common StockAcquired 10 000 @ $22,99grant · 2026-05-04

    Actions

    Ask Handelsavisen

    — missing data
    Data sources
    • Market data
    • Market data cache
    • Issuer disclosures
    • Public news
    • Earnings transcripts
    • Consensus estimates
    • ESG data
    How metrics are computed
    • Dilution Ratio
      (shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
    Source documents
    • Invicta Diagnostic Ltd Market data — financials · 2026-05-28

    Ownership & reference

    Top holders

    • Arrowstreet Capital, Limited PartnershipInvestment Managers · as of 2026-03-310,02 %$44M
    • American Century Investment Management, Inc.Investment Managers · as of 2026-03-310,02 %$45M
    • Dimensional Fund Advisors, L.P.Investment Managers · as of 2026-03-310,02 %$103M
    • Victory Capital Management Inc.Investment Managers · as of 2026-03-310,01 %$12M
    • AQR Capital Management, LLCInvestment Managers · as of 2026-03-310,01 %$12M
    • Principal Global Investors (Equity)Investment Managers · as of 2026-03-310,01 %$10M
    • Goldman Sachs Asset Management, L.P.Investment Managers · as of 2026-03-310,00 %$37M
    • First Trust Advisors L.P.Investment Managers · as of 2026-03-310,00 %$6M
    • Charles Schwab Investment Management, Inc.Investment Managers · as of 2026-03-310,00 %$27M
    • Invesco QQQ TrustFunds · as of 2026-03-310,00 %$21M
    • Geode Capital Management, L.L.C.Investment Managers · as of 2026-03-310,00 %$45M
    • State Street Investment Management (US)Investment Managers · as of 2026-03-310,00 %$71M
    • Northern Trust Investments, Inc.Investment Managers · as of 2026-03-310,00 %$18M
    • Vanguard Capital Management, LLCInvestment Managers · as of 2025-12-310,00 %$158M
    • Bank of New York Mellon CorpInstitutional Investor · as of 2026-03-310,00 %$11M
    • Morgan Stanley Smith Barney LLCInvestment Managers · as of 2026-03-310,00 %$31M
    • UBS Financial Services, Inc.Investment Managers · as of 2026-03-310,00 %$10M
    • Nuveen LLCInvestment Managers · as of 2024-12-310,00 %$5M
    • Franklin Advisers, Inc.Investment Managers · as of 2026-03-310,00 %$6M
    • EATON VANCE MANAGEMENTInstitutional Investor · as of 2022-09-300,00 %$0M
    • Jennison Associates LLCInvestment Managers · as of 2026-03-310,00 %$2M
    • AMERIPRISE FINANCIAL INCInstitutional Investor · as of 2026-03-310,00 %$4M
    • AllianceBernstein L.P.Investment Managers · as of 2026-03-310,00 %$2M
    • JANUS HENDERSON GROUP PLCInstitutional Investor · as of 2026-03-310,00 %$1M
    • T. Rowe Price Associates, Inc.Investment Managers · as of 2026-03-310,00 %$0M
    • PNC Investments LLCInvestment Managers · as of 2026-03-310,00 %$0M
    • Wells Fargo AdvisorsBrokerage Firms · as of 2026-03-310,00 %$1M
    • Wellington Management Company, LLPInvestment Managers · as of 2026-03-310,00 %$1M
    • FMR LLCInstitutional Investor · as of 2026-03-310,00 %$2M
    • BlackRock Institutional Trust Company, N.A.Investment Managers · as of 2024-06-300,00 %$1M
    • JONES FINANCIAL COMPANIES LLLPInstitutional Investor · as of 2026-03-310,00 %$0M
    • PNC Investments LLCInvestment Managers · as of 2026-03-310,00 %$0M

    Insider activity

    Mixed / flat0 buys · 0 sellsnet $08 insiders · last 365d
    • Zhen MarianneChief Accounting Officer · Common StockOther 1 127 @ $22,24$25K · 2026-05-20
    • Basso StephenChief Financial Officer · Common StockOther 559 @ $22,24$12K · 2026-05-20
    • Raifeld PavelDirector, Chief Executive Officer · Common StockOther 1 130 @ $22,24$25K · 2026-05-20
    • Linden JosephineDirector · Common StockOther 5 733 · 2026-05-18
    • Linden JosephineDirector · Common StockOther 9 461 · 2026-05-18
    • Basso StephenChief Financial Officer · Common StockOther 1 123 · 2026-05-15
    • Raifeld PavelDirector, Chief Executive Officer · Common StockOther 1 123 · 2026-05-15
    • Schlesinger Sarah J.Director · Common StockOther 9 786 · 2026-05-04
    • Basso StephenChief Financial Officer · Common StockOther 37 994 · 2026-05-04
    • Small Derek ADirector · Common StockOther 9 786 · 2026-05-04
    • Raifeld PavelDirector, Chief Executive Officer · Common StockOther 126 646 · 2026-05-04
    • DiPaolo MarkDirector · Common StockOther 9 786 · 2026-05-04
    • Haimovitz JulesDirector · Common StockOther 9 786 · 2026-05-04
    • Zhen MarianneChief Accounting Officer · Common StockOther 12 766 · 2026-05-04
    • Zhen MarianneChief Accounting Officer · Common StockOther 2 460 @ $23,39$58K · 2026-02-20
    • Basso StephenChief Financial Officer · Common StockOther 1 244 @ $23,39$29K · 2026-02-20
    • Raifeld PavelDirector, Chief Executive Officer · Common StockOther 2 986 @ $23,39$70K · 2026-02-20
    • Zhen MarianneChief Accounting Officer · Common StockOther 992 @ $21,16$21K · 2025-11-20
    • Basso StephenChief Financial Officer · Common StockOther 237 @ $21,16$5K · 2025-11-20
    • Basso StephenChief Financial Officer · Common StockOther 604 · 2025-11-15
    • Basso StephenChief Financial Officer · Common StockOther 27 609 @ $18,11$500K · 2025-11-03
    • Raifeld Pavel10% owner · Common StockOther 110 436 @ $18,11$2,0M · 2025-11-03
    • Basso StephenChief Financial Officer · Common StockOther 237 @ $19,95$5K · 2025-08-20
    • Zhen MarianneChief Accounting Officer · Common StockOther 991 @ $19,95$20K · 2025-08-20

    Short positioning

    7.0Mshares short+5.6% vs prior
    7.54days to cover
    52.4%short of daily vol
    27.8Kfails-to-deliver
    as of 2026-07-15 · short-interest report (free)

    Geographic breakdown

    — missing data
    Listings · one canonical issuer all listings resolve to the canonical
    INVA.NSCanonical
    NSE (India) · USD

    Intel & risk

    PredictorBeat prob45 %Surprise-0,08M&A prob3 %Full forecast →
    peak dispatch · —
    OSINT findings
    Dilution riskLow
    Liquidity riskUnknown
    Relationship graph
    INVAEX21:01bEX21:13fEX21:17eEX21:32fEX21:3a2EX21:405EX21:450EX21:4a3EX21:613EX21:669Healthcare Fac
    This companySectorSubsidiaries

    Evidence & claims

    From filings & derived data
    • Operating cash flow (YoY) (2025-12-31 vs 2024-12-31): 4.4%Derived (calculated)
    • EPS (basic) (YoY) (2025-12-31 vs 2024-12-31): 986.5%Derived (calculated)
    • Cash & equivalents (YoY) (2025-12-31 vs 2024-12-31): 80.7%Derived (calculated)
    • Revenue (YoY) (2025-12-31 vs 2024-12-31): 14.7%Derived (calculated)
    • Current ratio (FY 2025-12-31): 14.64xDerived (calculated)
    • Gross margin (FY 2025-12-31): 74.8%Derived (calculated)
    • Long-term debt (YoY) (2025-12-31 vs 2024-12-31): 0.6%Derived (calculated)
    • Gross profit (YoY) (2025-12-31 vs 2024-12-31): 3.9%Derived (calculated)
    • EPS (diluted) (YoY) (2025-12-31 vs 2024-12-31): 816.7%Derived (calculated)
    • Total assets (YoY) (2025-12-31 vs 2024-12-31): 25.7%Derived (calculated)
    • Shareholders' equity (YoY) (2025-12-31 vs 2024-12-31): 69.7%Derived (calculated)
    • Capex (YoY) (2025-12-31 vs 2024-12-31): 318.9%Derived (calculated)
    • R&D expense (YoY) (2025-12-31 vs 2024-12-31): 124.1%Derived (calculated)
    • Operating income (YoY) (2025-12-31 vs 2024-12-31): -1.9%Derived (calculated)
    • Revenue (annual): USD 411.33MSEC XBRL filing
    • Pre-tax income (annual): USD 326.86MSEC XBRL filing
    • Total assets (annual): USD 1.64BSEC XBRL filing
    • EPS (diluted) (annual): USD-PER-SHARES 3SEC XBRL filing
    • Operating income (annual): USD 163.75MSEC XBRL filing
    • Operating cash flow (annual): USD 196.93MSEC XBRL filing
    • Total operating expenses (annual): USD 143.92MSEC XBRL filing
    • Long-term debt (annual): USD 257.73MSEC XBRL filing
    • Current assets (annual): USD 727.51MSEC XBRL filing
    • Shares outstanding (annual): 74.64MSEC XBRL filing
    Showing 24 of 60 surfaced claims.
    Atomic claims from regulatory filings and derived calculations. Provenance shown as source kind only.

    The Thread

    Everything we know, in order
    2026-10-28EVENTUpcomingQ3 2026 earnings (expected) estimated date
    2026-07-03 03:12 UTCHOLDERInstitutional holding changed
    2026-07-03 03:12 UTCHOLDER1 institutional position change flagged (1 major)
    2026-06-30 03:38 UTCEARNINGSUpcomingForecast: earnings_forecast (90d)
    2026-06-30 03:38 UTCEARNINGSUpcomingForecast: ma_probability (180d)
    2026-06-28 03:14 UTCHOLDERInstitutional holding changed
    2026-06-28 03:14 UTCHOLDERInstitutional holding changed
    2026-06-28 03:14 UTCHOLDER2 institutional position changes flagged (1 major)
    2026-06-24 03:12 UTCHOLDERInstitutional holding changed
    2026-06-24 03:12 UTCHOLDER1 institutional position change flagged (1 major)
    2026-06-21 02:57 UTCHOLDERInstitutional holding changed
    2026-06-21 02:57 UTCHOLDER1 institutional position change flagged (1 major)
    2026-05-20 00:00 UTCINSIDER22 insider transactions — 2026-05 8 derivative
    2026-05-20INSIDERZhen Marianne transacted 1.1k sh — Chief Accounting Officer ~$25k
    2026-05-20INSIDERBasso Stephen transacted 559 sh — Chief Financial Officer ~$12k
    2026-05-20INSIDERRaifeld Pavel transacted 1.1k sh — Director, Chief Executive Officer ~$25k
    2026-05-18FILING8-K filing →
    2026-05-18INSIDERLinden Josephine transacted 5.7k sh — Director
    2026-05-18INSIDERLinden Josephine transacted 9.5k sh — Director
    2026-05-18INSIDERLinden Josephine acquired 9.2k sh Non-statutory Stock Option — Director
    2026-05-15INSIDERBasso Stephen transacted 1.1k sh — Chief Financial Officer
    2026-05-15INSIDERRaifeld Pavel transacted 1.1k sh — Director, Chief Executive Officer
    2026-05-06FILING10-Q filing →
    2026-05-06FILING8-K filing →
    2026-05-04FILING8-K filing →
    2026-05-04INSIDERSchlesinger Sarah J. transacted 9.8k sh — Director
    2026-05-04INSIDERBasso Stephen transacted 38.0k sh — Chief Financial Officer
    2026-05-04INSIDERSmall Derek A transacted 9.8k sh — Director
    2026-05-04INSIDERRaifeld Pavel transacted 126.6k sh — Director, Chief Executive Officer
    2026-05-04INSIDERDiPaolo Mark transacted 9.8k sh — Director
    2026-05-04INSIDERHaimovitz Jules transacted 9.8k sh — Director
    2026-05-04INSIDERZhen Marianne transacted 12.8k sh — Chief Accounting Officer
    2026-05-04INSIDERSchlesinger Sarah J. acquired 10.0k sh Non-statutory Stock Option — Director
    2026-05-04INSIDERDiPaolo Mark acquired 10.0k sh Non-statutory Stock Option — Director
    2026-05-04INSIDERRaifeld Pavel acquired 312.5k sh Non-statutory Stock Option — Director, Chief Executive Officer
    2026-05-04INSIDERZhen Marianne acquired 31.5k sh Non-statutory Stock Option — Chief Accounting Officer
    2026-05-04INSIDERBasso Stephen acquired 93.8k sh Non-statutory Stock Option — Chief Financial Officer
    2026-05-04INSIDERSmall Derek A acquired 10.0k sh Non-statutory Stock Option — Director
    2026-05-04INSIDERHaimovitz Jules acquired 10.0k sh Non-statutory Stock Option — Director
    2026-03-24FILINGDEF 14A filing →
    Showing the 40 most recent of 62 entries.
    The entity's full life in the product — typed, chronological, joined across Newspaper, Platform and Data. Our memory, made visible.
    Sources filings · IR · transcripts · market data · tier hybrid · as of 2026-08-04 Market data · Issuer disclosures · Public news · Earnings transcripts · Consensus estimates · ESG data Premium coverage